Navigation Links
Adeona to Host First Quarter 2011 Investor Conference Call
Date:5/10/2011

ANN ARBOR, Mich., May 10, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (AMEX: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that it will hold its 1st quarter 2011 investor conference call on Tuesday, May 17, 2011, at 1:00pm EDT. James S. Kuo, M.D., M.B.A., Adeona's Chief Executive Officer, will host the call.  

The Company will be joined by special guest, Rhonda Voskuhl, M.D., Director, University of California, Los Angeles (UCLA) Multiple Sclerosis Program, UCLA Department of Neurology, and Lead Principal Investigator of the multi-center clinical trial evaluating Adeona's Trimesta™ (oral estriol) drug candidate for multiple sclerosis (MS) in women. Dr. Voskuhl is the investigator who discovered that the female sex hormone, estriol, could suppress MS-like symptoms in a mouse model of the disease.  This preclinical research led to a 10-patient clinical study that showed an 82% decrease in brain lesions over a six month period.  This clinical study was followed by a 150-patient, randomized, double-blind, placebo-controlled clinical trial of Trimesta that is currently underway at 15 centers in the United States. Dr. Voskuhl's preclinical and clinical work has been scientifically reviewed and awarded over $8 million in grant funding by organizations such as the National Institutes of Health, the National Multiple Sclerosis Society and other third party groups. In addition to providing an update of the Trimesta clinical trial, Dr. Voskuhl will share insights into her proposed new mechanism to treat MS patients and will take questions about her research.

Interested parties should call toll free 1-800-860-2442 (U.S.) or 1-866-605-3852 (Canada), or from outside North America +1 412-858-4600, fifteen minutes before the start of the call to register and identify themselves as registra
'/>"/>

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Adeona Executes Manufacturing and Supply Agreement with TG United for reaZin™
2. Adeonas Clinical Study of reaZin™ Meets Primary Outcomes of Increasing Serum Zinc and Decreasing Serum Free Copper
3. Adeona to Host Conference Call
4. Adeona to Raise $3.5 Million in Registered Direct Offering
5. Adeona Reports 2010 Year End Financial Results
6. Adeona to Host 2010 Year End Investor Conference Call
7. Adeonas Multiple Sclerosis Trial Receives $409,426 Grant
8. Adeona Receives Excellence in Science & Technology Award
9. Adeona Appoints George J. Brewer, M.D., Senior Vice President of Research & Development
10. Adeona Mourns the Passing of David A. Newsome, M.D., Senior Vice President of Research & Development
11. Adeonas Alzheimers Disease Pivotal Clinical Study Results Abstract Accepted for Presentation at the American Academy of Neurologys 63rd Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... España, September 2, 2014 ... fibrilación atrial muestran agentes antitrombóticos no utilizados óptimamente ... -- Las presentaciones de GARFIELD-AF en el ... tratamiento y los resultados de pacientes en riesgo ... --    Los datos de casi ...
(Date:9/2/2014)... Spain , September 2, 2014 ... at ESC CONGRESS 2014 provide insight into treatment ... in everyday clinical practice --   ... Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF), ... that stroke prevention strategies for atrial fibrillation (AF) ...
(Date:9/2/2014)... VIEJO, Calif. , Sept. 2, 2014  Avanir Pharmaceuticals, ... management will present an overview of the company at the ... . , Presentation date: Tuesday September 9, ... A live webcast and 30-day archive of this ... About Avanir Pharmaceuticals, Inc. Avanir Pharmaceuticals, Inc. ...
Breaking Medicine Technology:Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
... to treating MCLs nonsurgically, study findsROSEMONT, Ill., March 2 ... ligament (MCL) may be treated successfully without surgery, according ... issue of The Journal of the American Academy ... the review,s authors found, is properly diagnosing and understanding ...
... (Nasdaq: ARAY ), a global leader in ... CyberKnife lung cancer treatments in calendar year 2008. ... radiosurgery in the United States grew 52 percent from ... Additionally the overall number of patients treated with ...
Cached Medicine Technology:Treating Knee Ligament Injuries 2Treating Knee Ligament Injuries 3CyberKnife Radiosurgery for Lung Cancer Sees Increased Interest and Continued Rapid Growth 2CyberKnife Radiosurgery for Lung Cancer Sees Increased Interest and Continued Rapid Growth 3CyberKnife Radiosurgery for Lung Cancer Sees Increased Interest and Continued Rapid Growth 4
(Date:9/2/2014)... 02, 2014 Becker's Healthcare is ... and Chief Information Officer Strategy Roundtables on November ... Becker's Hospital Review Chief Executive Officer and Chief ... health system Chief Executive Officers, Chief Financial Officers, ... system executives through high-quality continuing education, networking ...
(Date:9/2/2014)... BambooIndustry.com, an excellent company in the bamboo industry, has ... floors to celebrate the coming of autumn. To ... frequent callers, BambooIndustry.com launched a promotion for its newly ... floors, BambooIndustry.com provides many kinds of wonderful items for ... floors, click lock floors, wide plank floors and so ...
(Date:9/2/2014)... pm EDT): In a Viewpoint published today in the ... team of Boston researchers call for the implementation of ... United States. The researchers from the Friedman School of ... and Boston Children,s Hospital write that policies taxing nearly ... help people make meaningful dietary changes and substantially reduce ...
(Date:9/2/2014)... 2014 TCG, a leading government technology strategy ... one of the fastest-growing companies in America for the seventh ... was previously recognized in 2013, 2012, 2011, 2010, 2009, 2008, ... grown 86% from 2010 to 2013, ranking the company at ... in America - up 635 spots from 2013! More information ...
(Date:9/2/2014)... New York, NY (PRWEB) September 02, 2014 ... and other new blood thinners is growing at a ... ) continue to mount in courts around the U.S., ... published in American Journal of Medicine, within a year ... to be prescribed Xarelto as warfarin, a blood thinner ...
Breaking Medicine News(10 mins):Health News:Becker's Healthcare Announces Hospital CEO and CIO Strategy Roundtables 2Health News:Becker's Healthcare Announces Hospital CEO and CIO Strategy Roundtables 3Health News:Becker's Healthcare Announces Hospital CEO and CIO Strategy Roundtables 4Health News:Cheap Strand Woven Bamboo Floors For Autumn On Sale At BambooIndustry.com 2Health News:Taxes and subsidies could encourage healthier diet and lower healthcare costs 2Health News:TCG One of the Fastest-Growing Companies in America – for the Eighth Time! 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 3Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 4
... that feeding tubes do not improve survival rates or ... their frequency of use varies widely across the states. ... surrounding the decision to place feeding tubes surgically are ... that often affects a patient,s ability to eat. In ...
... People with dementia may soon have improved oral hygiene ... four-year grant to Rita A. Jablonski, assistant professor of ... disease have all been linked to poor oral hygiene. ... for because they often are no longer able to ...
... to predict the risk of disease progression and response ... for high- and low-risk patients, but do not always ... a new analysis shows. In recent years, ... information for breast cancer. Dr Catherine Kelly from Mater ...
... COLUMBUS, Ohio In a rare and medically remarkable operation, ... Comprehensive Cancer Center Arthur G. James Cancer Hospital and ... left leg, hip and pelvis of a cancer patient, and ... completely rebuild the connection between his spine and remaining right ...
... 4 (HealthDay News) -- U.S. health officials issued final ... liquid over-the-counter drug products that are measured and dispensed ... The U.S. Food and Drug Administration developed the ... overdoses when using liquid over-the-counter (OTC) pain relievers, cold ...
... WEDNESDAY, May 4 (HealthDay News) -- A gene essential to ... heart defects that cause a major proportion of childhood death ... cardiac defects -- all malformations of the left ventricular outflow ... component may play a role. "It is estimated that ...
Cached Medicine News:Health News:Families need to know more about feeding tubes for elderly dementia patients 2Health News:Breast cancer multi-gene tests compared 2Health News:Breast cancer multi-gene tests compared 3Health News:Ohio State surgeons rebuild pelvis of cancer patient 2Health News:Ohio State surgeons rebuild pelvis of cancer patient 3Health News:FDA Issues Guidelines for Liquid OTC Medicines 2Health News:New Gene Linked to Congenital Heart Defects 2
... maximum positioning flexibility while permitting the components to ... easy transport. The system has a small footprint ... at the same time offers the surgeon total ... camera and display of the Stealthstation Treon can ...
... system for ENT, cranial and spine ... preoperatively, critical zones visible during tracking. ... vision, one button freezes image, snapshot ... Microscope interface: tracks focal point of ...
...
...
Medicine Products: